Suppr超能文献

镰状细胞视网膜病变和黄斑病变的临床及实验室风险因素:当前证据的范围综述

Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence.

作者信息

Brandsen Rajani P, Diederen Roselie M H, Kocabas Gizem, Nur Erfan, Malekzadeh Arjan, Schlingemann Reinier O, Biemond Bart J

机构信息

Department of Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam.

Department of Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam.

出版信息

Haematologica. 2025 May 1;110(5):1092-1104. doi: 10.3324/haematol.2024.286420. Epub 2024 Dec 19.

Abstract

Sickle cell retinopathy (SCR) is a complication of sickle cell disease (SCD) and can drastically impair visual acuity. Screening for SCR is, therefore, recommended, but evidence for optimal screening frequency on an individual level is lacking. This scoping review mapped the current evidence on risk factors for SCR and sickle cell maculopathy (SCM). A literature search (in Medline [Ovid]), Embase [Ovid]), and Scopus) resulted in 67 included articles which covered demographic risk factors, genetic risk factors, systemic therapy, correlations with other forms of SCD-related organ damage, and hematologic risk factors. SCR risk factors include older age, male sex, HbSC genotype, hemolysis, and HbF% <15% (in HbSS) and increased blood viscosity (in HbSC). For SCM, risk factors are older age, HbSS genotype, and higher degree of hemolysis. The pathophysiology of SCR and SCM appears multifactorial, but distinct patterns emerge suggesting that vaso-occlusion and hemolysis cause SCM and NPSCR in HbSS, while hyperviscosity in HbSC leads to peripheral retinopathy. We recommend yearly screening for high-risk patients (older HbSC males) and triennial screening for low-risk patients (young females HbSS with HbF>15%) to ensure comprehensive yet proportionate ophthalmic care. However, future studies are needed on the role of interventions for SCR and the long-term consequences of SCM in order to evaluate and define appropriate screening schedules.

摘要

镰状细胞视网膜病变(SCR)是镰状细胞病(SCD)的一种并发症,可严重损害视力。因此,建议对SCR进行筛查,但缺乏关于个体层面最佳筛查频率的证据。本综述梳理了目前关于SCR和镰状细胞性黄斑病变(SCM)危险因素的证据。通过在医学期刊数据库(Ovid平台)、Embase数据库(Ovid平台)和Scopus数据库进行文献检索,最终纳入67篇文章,这些文章涵盖了人口统计学危险因素、遗传危险因素、全身治疗、与其他形式SCD相关器官损害的相关性以及血液学危险因素。SCR的危险因素包括年龄较大、男性、HbSC基因型、溶血、HbF%<15%(HbSS型)以及血液粘度增加(HbSC型)。对于SCM,危险因素为年龄较大、HbSS基因型和较高程度的溶血。SCR和SCM的病理生理学似乎是多因素的,但呈现出不同模式,表明血管阻塞和溶血在HbSS型中导致SCM和非增殖性镰状细胞视网膜病变(NPSCR),而HbSC型中的高粘度导致周边视网膜病变。我们建议对高危患者(年龄较大的HbSC男性)每年进行筛查,对低危患者(HbF>15%的年轻HbSS型女性)每三年进行筛查,以确保全面且适度的眼科护理。然而,需要进一步研究SCR干预措施的作用以及SCM的长期后果,以便评估和确定合适的筛查时间表。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4f/12050931/d3f79d073fed/1101092.fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验